318 related articles for article (PubMed ID: 25754123)
1. CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.
Kumai T; Nagato T; Kobayashi H; Komabayashi Y; Ueda S; Kishibe K; Ohkuri T; Takahara M; Celis E; Harabuchi Y
Cancer Immunol Immunother; 2015 Jun; 64(6):697-705. PubMed ID: 25754123
[TBL] [Abstract][Full Text] [Related]
2. The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity.
Scheu S; Ali S; Ruland C; Arolt V; Alferink J
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099057
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-positive pyothorax-associated lymphoma expresses CCL17 and CCL22 chemokines that attract CCR4-expressing regulatory T cells.
Higuchi T; Matsuo K; Hashida Y; Kitahata K; Ujihara T; Taniguchi A; Yoshie O; Nakayama T; Daibata M
Cancer Lett; 2019 Jul; 453():184-192. PubMed ID: 30953706
[TBL] [Abstract][Full Text] [Related]
4. Surrogate antibodies that specifically bind and neutralize CCL17 but not CCL22.
Santulli-Marotto S; Fisher J; Petley T; Boakye K; Panavas T; Luongo J; Kavalkovich K; Rycyzyn M; Wu B; Gutshall L; Coelho A; Hogaboam CM; Ryan M
Monoclon Antib Immunodiagn Immunother; 2013 Jun; 32(3):162-71. PubMed ID: 23750473
[TBL] [Abstract][Full Text] [Related]
5. Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis.
Yogo Y; Fujishima S; Inoue T; Saito F; Shiomi T; Yamaguchi K; Ishizaka A
Respir Res; 2009 Aug; 10(1):80. PubMed ID: 19715610
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.
Yoshino K; Kishibe K; Nagato T; Ueda S; Komabayashi Y; Takahara M; Harabuchi Y
Br J Haematol; 2013 Feb; 160(3):331-42. PubMed ID: 23206232
[TBL] [Abstract][Full Text] [Related]
7. Expression of chemokine receptor CCR4 and its ligands (CCL17 and CCL22) in murine contact hypersensitivity.
Kusumoto M; Xu B; Shi M; Matsuyama T; Aoyama K; Takeuchi T
J Interferon Cytokine Res; 2007 Nov; 27(11):901-10. PubMed ID: 18052724
[TBL] [Abstract][Full Text] [Related]
8. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells.
Mariani M; Lang R; Binda E; Panina-Bordignon P; D'Ambrosio D
Eur J Immunol; 2004 Jan; 34(1):231-40. PubMed ID: 14971049
[TBL] [Abstract][Full Text] [Related]
9. [Changes of TRGV genes and prognosis-related chemokine/receptor gene expressions in T cell lymphoma].
Luo Q; Jin Z; Chen S; Yang L; Li B; Li W; Li Y; Wu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Mar; 33(3):362-366. PubMed ID: 28274317
[TBL] [Abstract][Full Text] [Related]
10. CCL17 acts as an antitumor chemokine in micromilieu-driven immune skewing.
Li Y; Cao H; Jiang Z; Yan K; Shi J; Wang S; Wang F; Wang W; Li X; Sun N; Liu L; Chen L; Chen Y; Guo R; Song Y
Int Immunopharmacol; 2023 May; 118():110078. PubMed ID: 37001380
[TBL] [Abstract][Full Text] [Related]
11. Evidence that phospholipase-C-dependent, calcium-independent mechanisms are required for directional migration of T-lymphocytes in response to the CCR4 ligands CCL17 and CCL22.
Cronshaw DG; Kouroumalis A; Parry R; Webb A; Brown Z; Ward SG
J Leukoc Biol; 2006 Jun; 79(6):1369-80. PubMed ID: 16614259
[TBL] [Abstract][Full Text] [Related]
12. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy.
Viney JM; Andrew DP; Phillips RM; Meiser A; Patel P; Lennartz-Walker M; Cousins DJ; Barton NP; Hall DA; Pease JE
J Immunol; 2014 Apr; 192(7):3419-27. PubMed ID: 24563252
[TBL] [Abstract][Full Text] [Related]
13. CCR4 and its ligands: from bench to bedside.
Yoshie O; Matsushima K
Int Immunol; 2015 Jan; 27(1):11-20. PubMed ID: 25087232
[TBL] [Abstract][Full Text] [Related]
14. CCL22-specific Antibodies Reveal That Engagement of Two Distinct Binding Domains on CCL22 Is Required for CCR4-mediated Function.
Santulli-Marotto S; Wheeler J; Lacy ER; Boakye K; Luongo J; Wu SJ; Ryan M
Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):373-80. PubMed ID: 26683175
[TBL] [Abstract][Full Text] [Related]
15. CCL17 and CCL22 induce CCR4 receptor expression and promote cytokine-induced killer cells migration.
Dong Y; Gao S; Zhang X; Kou J; Liu J; Ye T; Shen H
Anticancer Drugs; 2022 Feb; 33(2):149-157. PubMed ID: 34657098
[TBL] [Abstract][Full Text] [Related]
16. Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder.
Takegawa S; Jin Z; Nakayama T; Oyama T; Hieshima K; Nagakubo D; Shirakawa AK; Tsuzuki T; Nakamura S; Yoshie O
Cancer Sci; 2008 Feb; 99(2):296-302. PubMed ID: 18271928
[TBL] [Abstract][Full Text] [Related]
17. Circulating Epstein-Barr virus-encoded micro-RNAs as potential biomarkers for nasal natural killer/T-cell lymphoma.
Komabayashi Y; Kishibe K; Nagato T; Ueda S; Takahara M; Harabuchi Y
Hematol Oncol; 2017 Dec; 35(4):655-663. PubMed ID: 27709652
[TBL] [Abstract][Full Text] [Related]
18. EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22.
Jorapur A; Marshall LA; Jacobson S; Xu M; Marubayashi S; Zibinsky M; Hu DX; Robles O; Jackson JJ; Baloche V; Busson P; Wustrow D; Brockstedt DG; Talay O; Kassner PD; Cutler G
PLoS Pathog; 2022 Jan; 18(1):e1010200. PubMed ID: 35025968
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
[TBL] [Abstract][Full Text] [Related]
20. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.
Ohuchi K; Fujimura T; Lyu C; Amagai R; Muto Y; Aiba S
Dermatol Ther; 2020 Nov; 33(6):e14099. PubMed ID: 32725764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
